136476-38-5Relevant articles and documents
SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS
-
Paragraph 0233, (2021/07/31)
Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.
A Spiroalkylation Method for the Stereoselective Construction of α-Quaternary Carbons and Its Application to the Total Synthesis of (R)-Puraquinonic Acid
Elmehriki, Adam A. H.,Gleason, James L.
, p. 9729 - 9733 (2019/12/02)
Cyclic α-quaternary carbon stereocenters were prepared from biselectrophillic substrates and an easily prepared chiral bicyclic sulfonyl lactam. This was achieved in two steps by spiroalkylation, employing biphasic reaction conditions with a phase-transfer catalyst, followed by reduction and alkylation with a series of alkyl halide electrophiles. The products of this method were isolated in good yields with with high levels of diastereoselectivity. This methodology was employed in the enantioselective total synthesis of (R)-puraquinonic acid (1) for a late-stage installation of the α-quaternary carbon stereocenter. This enabled the shortest synthesis of 1 to date, an eight-pot sequence providing an overall yield of 14%.
Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects in Vivo
Velcicky, Juraj,Bodendorf, Ursula,Rigollier, Pascal,Epple, Robert,Beisner, Daniel R.,Guerini, Danilo,Smith, Philip,Liu, Bo,Feifel, Roland,Wipfli, Peter,Aichholz, Reiner,Couttet, Philippe,Dix, Ina,Widmer, Toni,Wen, Ben,Brandl, Trixi
supporting information, p. 865 - 880 (2018/02/17)
Signal peptide peptidase-like 2a (SPPL2a) is an aspartic intramembrane protease which has recently been shown to play an important role in the development and function of antigen presenting cells such as B lymphocytes and dendritic cells. In this paper, we describe the discovery of the first selective and orally active SPPL2a inhibitor (S)-2-cyclopropyl-N1-((S)-5,11-dioxo-10,11-dihydro-1H,3H,5H-spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1′-cyclopropan]-10-yl)-N4-(5-fluoro-2-methylpyridin-3-yl)succinamide 40 (SPL-707). This compound shows adequate selectivity against the closely related enzymes γ-secretase and SPP and a good pharmacokinetic profile in mouse and rat. Compound 40 significantly inhibited processing of the SPPL2a substrate CD74/p8 fragment in rodents at doses ≤10 mg/kg b.i.d. po. Oral dosing of 40 for 11 days at ≥10 mg/kg b.i.d. recapitulated the phenotype seen in Sppl2a knockout (ko) and ENU mutant mice (reduced number of specific B cells and myeloid dendritic cells). Thus, we believe that SPPL2a represents an interesting and druggable pharmacological target, potentially providing a novel approach for the treatment of autoimmune diseases by targeting B cells and dendritic cells.
NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY
-
Paragraph 00451; 00454, (2014/03/22)
The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases
SYNTHESIS OF ANTIVIRAL COMPOUND
-
Paragraph 0147; 0148; 0149, (2014/01/07)
The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.
PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF
-
Paragraph 0617-0618, (2013/11/06)
The invention relates to novel products of formula (Ia) or (Ib): these products being in all the isomeric forms and salts as drugs, notably as anticancer drugs.
MACROCYCLIC COMPOUNDS FOR MODULATING IL-17
-
Paragraph 00214, (2013/08/15)
The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of medical conditions
NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF
-
Page/Page column 57, (2012/02/01)
The invention relates to compounds of general formula (I) wherein R1,R2, R3, R4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use -alone or in
ORTHO-SUBSTITUTED HALOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE
-
Page/Page column 127, (2011/07/06)
Novel herbicides are provided. A haloalkylsulfonanilide derivative represented by the formula (1) or an agrochemically acceptable salt thereof: the formula (1): wherein A is -C(R7)(R8)- or -N(R9)-, W is an oxygen atom or a sulfur atom, n is an integer of from 1 to 4, R1 is halo C1 -C6 alkyl, R2 is a hydrogen atom, C1 - C6 alkyl or the like, each of R3 and R4 is independently a hydrogen atom, C1 - C6 alkyl or the like, each of R5, R6, R7 and R8 is independently a hydrogen atom, a halogen, C1 - C6 alkyl or the like, R9 is a hydrogen atom, C1 - C6 alkyl or the like, and X is halogen, C1 - C6 alkyl or the like.
4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS
-
Page/Page column 84; 85, (2008/06/13)
The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
